An Overview of the Rare Cotard’s (Walking Corpse) Syndrome


In 1880, Jules Cotard documented a characteristic syndrome after monitoring the unusual behavior of a 43-year-old woman.1 Known by the name Cotard’s Syndrome (CS), this extremely rare syndrome has still not been officially included in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM) or recognized by the World Health Organization’s International Classification of Diseases (ICD).  Although researchers have attempted to reinterpret CS and expand its horizons, its precise characterization has not been possible so far.1

Reported signs and symptoms

CS has been historically characterized by melancholic anxiety, suicidal tendencies, attempted self-infliction, delusions of damnation or possession, hypochondriac thoughts of non-existence or ruin of several organs, of the whole body, of the soul, of divinity, analgesia, and the idea of immortality.1 Other known signs and symptoms include denying the existence of the brain, mind, intellect, or the world in general. Denial of pregnancy and delusional paralysis have also been reported.2

Because the symptoms of CS develop over a period of time, researchers have proposed a three-stage model for the development of CS. The proposed CS model comprises a germination stage, a blooming stage, and a chronic stage. The germination stage is characterized by hypochondriasis and cenesthopathy. Symptoms of nihilistic delusions develop fully during the blooming stage. Chronic changes in mood and systematization of delusions are common during the last (chronic) stage.2

Etiology and pathogenesis

Most neuro-imaging data do not reveal any gross structural changes in the brain of patients with CS. Nevertheless, right frontal damage has commonly been reported in cases of delusional misidentification (including CS). Left lesions have also been reported. However, not all studies show right-sided hypofunctionality. In patients with neurological disorders, there is presumably a correlation between prefrontal dysfunction and nihilistic beliefs.3

Personality characteristics seem to play a key role in the development of CS. More importantly, the neuropsychological origin of CS is supposedly related to a malfunctioning information processing subsystem where face and body recognition are associated with a changed affective component. However, in the absence of this affective component, patients with CS may experience a feeling of derealization and depersonalization.3

Diagnosis and treatment

CS is also known to manifest itself with various diseases and physiological dysfunctions including, but not limited to, Parkinson’s disease, syphilis, epilepsy, cerebral trauma, brain tumors, migraine, postictal depression, and non‑herpetic encephalitis.2

An extensive literature survey reveals that depression is the most common diagnosis in patients presenting with CS. Accordingly, CS has been categorized into: (1) Psychotic depression (patients with melancholia and nihilistic delusions), (2) Cotard type 1, including the pure forms of nihilistic delusions without affective symptoms, and (3) Cotard type 2, with a mixed group of symptoms (depression, anxiety, and auditory hallucinations).2

Studies suggest that electroconvulsive therapy is effective in treating CS. However, case reports also highlight the benefits of antidepressants alone, antipsychotics alone, or a combination of both.2 Most patients benefit from a combination of medication and a form of talk therapy (e.g., psychotherapy or cognitive behavioral therapy).4


Further research is required to delineate the precise etiology of CS. A better understanding of this extremely rare disease will result into improved patient outcomes and more effective clinical interventions.


  1. Tomasetti C, Valchera A, Fornaro M, Vellante F, Orsolini L, Carano A, Ventriglio A, Di Giannantonio M, De Berardis D. The ‘dead man walking’ disorder: an update on Cotard’s syndrome. Int Rev Psychiatry. 2020 Aug-Sep;32(5–6):500–509. doi: 10.1080/09540261.2020.1769881. Epub 2020 Jun 5. PMID: 32500801.
  2. Grover S, Aneja J, Mahajan S, Varma S. Cotard’s syndrome: Two case reports and a brief review of literature. J Neurosci Rural Pract. 2014 Nov;5(Suppl 1):S59-62. doi: 10.4103/0976-3147.145206. PMID: 25540544; PMCID: PMC4271387.
  3. Debruyne H, Audenaert K. Towards understanding Cotard’s syndrome: an overview. Neuropsychiatry. 2012; 2(6), 481–486. doi: 10.2217/NPY.12.67
  4. Rath L. Cotard’s syndrome: What is it? [Internet]. WebMD. WebMD; [Accessed 2022 Sep 15]. Available from:
Share it with

Similar Articles

Data Privacy Notice

This Privacy Notice shall be read in conjunction with the Privacy Policy to the extent this Notice does not mention or specify the particulars that should have been mentioned or specified relating to the Notice in pursuance of the provisions of the Data Protection Laws as applicable.

On having accessed or visited this Platform you the Noticee hereby voluntarily consent to and take notice of the fact that the personal data, by which or in relation whereto you the concerned Noticee is identifiable, shall be retained, stored, used, and may be processed by the Company for the purpose and in the manner, though legal, found suitable to it for commercial and/or some other reasons. The detailed specificity whereof may be found in the Privacy Policy. The consent provided herein may be withdrawn anytime by you, the Noticee, at its own volition by removing your profile or by writing to us at

As a Noticee, you shall have the right to grievance redressal, in relation to your consent or our use of your personal data, which you may address by writing to us at Should you, the Noticee, thereafter remain unsatisfied or dissatisfied with the resolution provided by us, you, the Noticee, may approach the concerned regulatory authority for the redressal of your grievance.

Thanks for exploring our medical content.

Create your free account or log in to continue reading.

Data Privacy Notice

By using this platform, you consent to our use of your personal data as detailed in our Privacy Policy, and acknowledge that we use cookies to improve your browsing experience